Lilly, Boehringer submit diabetes drug to FDA

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Eli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker Boehringer Ingelheim to the Food and Drug Administration.

Lilly said the treatment, a once-daily tablet named empagliflozin, belongs to a class of drugs that aim to reduce blood sugar levels in patients by blocking glucose reabsorption in the kidney and removing excess glucose through urine. The drug does not depend on a patient's insulin levels to be effective, unlike other treatments.

Type 2 is the most common form of diabetes, a chronic disease in which a person's body doesn't properly produce or use the hormone insulin.

Lilly said in January that empagliflozin proved more effective than a placebo in initial results from several late-stage studies. The Indianapolis-based company will present more details on the studies at the American Diabetes Association annual meeting in June.

A Lilly spokeswoman declined to say when the FDA expects to make its decision on whether to approve the drug.

Lilly and Boehringer started teaming up in 2011 to design and sell several diabetes treatments.

Lilly shares fell 26 cents, to $55.31 each, in afternoon trading after hitting a 52-week high of $55.79 earlier in the session.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In